General Topics

General Topics Worldwide Healthcare Products researches, develops and manufactures its own brands of cosmetic products, food supplements and medical devices for topical use in the fields of dermatology, aesthetic medicine and cosmetology.  The group was founded in 1992 in Italy by Dr. Gianfranco de Paoli Ambrosi. It has 2 subsidiaries, one in Poland and one in Germany and distributes its products in more than 40 countries worldwide. General Topics has a multi-brand strategy with 4 distinctive brands:

SYNCHROLINE: Cosmetics, food supplements and Medical Devices. Skincare products and protocols dedicated to the treatment of various skin conditions. Target Market: Prescriptive (i.e. Dermatologists) and Pharmacies.TEBITECH: Medical and dermo-cosmetic devices for outpatient use - Chemical peelings and skincare products to be used prior, during and after medical procedures and surgeries. Target Market: Aesthetic clinics and cosmetic surgeons

FILLAST: Technological Luxury cosmetics. Anti-ageing: an innovative market created by General Topics where science and technology come together in the concept of luxury. Target Market: End user

Dr de Paoli: Exclusive products from Dr. De Paoli’s pharmacy: cosmetic products for various needs. Target Market: Pharmacies and Supermarkets

The result of General Topic's scientifically dynamic sprit led to 30 patents (PCT) in various countries, among which the USA, Europe, and China. The patents protect the ownership rights of the cosmetic products, pharmaceuticals, medical devices, and generic devices that have been created in the company.

General Topics' mission is to be an international leader in the dermatological and cosmetic industry. Product innovation, intellectual property protection and brand internationalization are the company's foundation. Our scientific marketing key messages derive from the R&D phases of each product. To this date, more than 150 products have been researched, developed, and manufactured.General Topics is open towards a scientific and technological future where knowledge is conceived as infinite, with infinite possibility of evolution. The embryonic phase of scientific research evolves beyond the experimental, chemo-physical, biochemical, and clinical verification phase. We believe in our ability to build our own strength in the market, and we believe that THE FUTURE IS OPEN.